| Multiple Sclerosis |
1 |
1 |
| Clinical Guidelines |
0 |
0.99 |
| Pregnancy |
0 |
0.78 |
| Treatment Guidelines |
0 |
0.98 |
| COVID-19 |
0 |
0.39 |
| Patient Safety |
0 |
0.31 |
| Adverse Effects |
0 |
0.24 |
| Drug and Treatment Safety |
0 |
0.24 |
| Europe |
0 |
0.24 |
| Glatiramer Acetate |
0 |
0.24 |
| Secondary Progressive Multiple Sclerosis |
0 |
0.24 |
| Biologic Therapy |
0 |
0.23 |
| Breastfeeding |
0 |
0.12 |
| Family Planning |
0 |
0.12 |
| Monoclonal Antibody |
0 |
0.12 |
| Relapsing Remitting Multiple Sclerosis |
0 |
0.97 |
| Shared Decision-Making |
0 |
0.12 |
| Progressive Multifocal Leukoencephalopathy |
0 |
0.09 |
| Contraception |
0 |
0.08 |
| Antineoplastic Drug |
0 |
0.06 |
| Clinically Isolated Syndrome (CIS) |
0 |
0.06 |
| Disability |
0 |
0.06 |
| Health Care Quality, Access, and Evaluation |
0 |
0.96 |
| Immunization |
0 |
0.06 |
| JC Virus |
0 |
0.06 |
| Leukoencephalopathy |
0 |
0.06 |
| Liver |
0 |
0.06 |
| Multiple Sclerosis Treatment |
0 |
0.95 |
| Newborn |
0 |
0.06 |
| Pandemic |
0 |
0.06 |
| Pharmacokinetics |
0 |
0.06 |
| Primary Progressive Multiple Sclerosis |
0 |
0.94 |
| Social Determinants of Health |
0 |
0.04 |